Advaxis Stumbles Further As Amgen Exits Early-Stage Cancer Immunotherapy Pact
Troubled by a clinical hold for another program, Advaxis now regains all rights to ADXS-NEO, a personalized immunotherapy in Phase I for cervical and head-and-neck cancers.
You may also be interested in...
As it moves away from virology, Gilead’s signs fibrosis collaboration with Scholar Rock. Novartis seeks to acquire CMDO that manufactures Kymriah, while Intrexon regains control of CAR-T program partnered with Merck KGAA. More deals from over the holiday period…
The FDA has placed a clinical hold on a Phase I/II trial for HPV-related cancers of Advaxis' axalimogene filolisbac in combination with Imfinzi after a patient died due to respiratory failure but analysts at Jefferies believe the fault could lie with AstraZeneca's PD-L1 inhibitor.
Amgen is the leader in approved bispecific antibodies and oncolytic viruses, but the company's not shy about expanding its oncology pipeline with even more modes of delivering medicines to cancer patients.